LASEROPTEK's PALLAS laser system is a UVB laser that is FDA-cleared to treat inflammatory skin conditions and can be used either as a monotherapy, or in conjunction with other FDA approved modalities.

Neil Shah, MD, is now a national key opinion leader (KOL) for LASEROPTEK's PALLAS UVB laser system for inflammatory skin conditions.

LASEROPTEK's PALLAS laser system is a UVB laser that is US Food and Drug Administration (FDA) -cleared to treat inflammatory skin conditions and can be used either as a monotherapy, or in conjunction with other FDA approved modalities.

Dr. Shah is a board-certified dermatologist and Medical Director of Clarus Dermatology, with offices throughout Minneapolis.  "I continuously search for innovations that improve the quality and efficacy of the care we provide our patients. The PALLAS UVB laser for targeted phototherapy represents a breath of fresh air in a market segment that has seen little to no technological advancement for many years," says Dr. Shah in a news release. "I respect LASEROPTEK's commitment to continuous development of novel solid-state laser technologies delivering both clinical and commercial efficacy.” "Dr. Shah's intimate understanding of PALLAS' unique benefits for both patients and clinicians, combined with his in-depth knowledge of the U.S. targeted laser phototherapy market provides us and our clinician customers an invaluable resource," says Christopher Dalton, Vice President of LASEROPTEK. "We appreciate Dr. Shah's commitment to technical and clinical innovation and are pleased to welcome him to LASEROPTEK's KOL advisory team."